Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.65Last Year’s EPS
-1.36Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized material positive corporate milestones — regulatory approvals across major markets, immediate commercial readiness and early uptake indicators, large full-year revenue growth driven by collaboration milestones, and a strong cash balance — which collectively mark the company’s transition to a global commercial-stage biopharmaceutical company. Notwithstanding, costs have increased substantially as the company invests in commercial infrastructure and ongoing clinical programs, driving wider net losses and near-term uncertainty around product sales and ACACIA topline details. On balance, the strategic and operational positives (approvals, launch momentum, pipeline catalysts and strong cash runway) outweigh the financial short-term headwinds and information gaps, yielding a constructive but cautious outlook.Company Guidance
Regulatory Approvals and Global Commercial Transition
MYCorzo (aficamten) received FDA approval in the U.S., approval in China, a positive CHMP opinion and subsequent European Commission approval for the EU during the same week — enabling Cytokinetics' transition to a global commercial-stage company and planned first European launch in Germany in Q2 2026.
Early U.S. Commercial Launch Momentum
Commercial launch activities began immediately after FDA approval with REMS portal and patient support program live; first prescriptions dispensed within days and patients on therapy within the first week. Within three weeks, over 700 HCPs were REMS-certified and the company reported over 12,000 customer engagements, with Cardiovascular Account Specialists engaging over 95% of the 700 HCPs identified as high-prescribers.
Strong Full-Year Revenue Lift Driven by Collaborations and Milestones
Total revenues for full-year 2025 were $88.0M versus $18.5M in 2024, an increase of approximately +376%, primarily due to a $52.4M technology transfer to Bayer and $15.0M in approval-related milestones under the Sanofi license agreement.
Robust Cash Position Entering Commercial Phase
Year-end 2025 cash, cash equivalents and investments totaled approximately $1.22B (versus $1.25B at year-end 2024). The 2025 balance included a $100M drawing from the Royalty Pharma loan; excluding that draw, cash would have declined by about $134M during 2025.
Clinical Development Milestones and Trial Progress
Key near-term clinical milestones: topline results for ACACIA-HCM (non-obstructive HCM) expected in Q2 2026; sNDA for MAPLE-HCM submitted with FDA review expected by Q4 2026; Health Canada review accepted with potential approval later in 2026. Ongoing trials: COMMUN-HF has 100% U.S. site activation and >90% European site activation; AMBER-HFpEF cohort one enrollment expected complete Q1 2026.
Positive Clinical Data Narrative
MAPLE-HCM responder analyses showed significantly more patients on aficamten achieved positive responses vs metoprolol, with greater improvements in symptoms and cardiac biomarkers — results that have resonated in the cardiology community and support commercial messaging.
Launch Targets and Strategic Priorities
Company aims to achieve >50% of CMI new patient preference share by 2026, intends to grow the overall CMI category, and set capital allocation priorities on US launch, European readiness, label-expansion opportunities, and advancing pipeline programs.
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $70.10 | $62.89 | -10.29% |
Nov 05, 2025 | $59.19 | $60.30 | +1.88% |
Aug 07, 2025 | $35.25 | $34.11 | -3.23% |
May 06, 2025 | $33.97 | $33.04 | -2.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2026 (Q1) is -1.65.